Jim Wassil, Executive Vice President, Chief Scientific Officer, and Chief Operating Officer of Vaxcyte, Inc., filed a Form 4 on November 4, 2026, disclosing a stock option exercise and two open-market sales of common stock executed on November 2, 2026, under a pre-established Rule 10b5-1 trading plan.
Key Highlights
- Option exercise: Wassil exercised a fully vested stock option to acquire 2,250 shares of common stock at an exercise price of $5.35 per share on November 2, 2026.
- First sale: 1,907 shares were sold at a weighted-average price of $60.779, with individual sale prices ranging from $60.385 to $61.24.
- Second sale: 343 shares were sold at a weighted-average price of $61.57, with individual sale prices ranging from $61.40 to $61.88.
- Remaining holdings: Following all reported transactions, Wassil directly held 145,435 shares of common stock.
- Remaining options: Wassil holds 44,148 stock options (right to buy) with an exercise price of $5.35 and an expiration date of April 17, 2030.
- 10b5-1 plan: The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025, according to the filing.
Wassil's November 2 Option Exercise and Share Sales at Vaxcyte
According to the Form 4 filed with the SEC on November 4, 2026, Jim Wassil, who serves as EVP, Chief Scientific Officer, and COO of Vaxcyte, Inc. (NASDAQ:PCVX), reported three transactions in the company's common stock, all dated November 2, 2026. The filing indicates the reporting person's address is listed as c/o Vaxcyte, Inc., 825 Industrial Road, Ste. 300, San Carlos, California 94070.
The filing discloses that Wassil first exercised a stock option to acquire 2,250 shares at $5.35 per share (transaction code M). The option was described as "fully vested and exercisable," with an expiration date of April 17, 2030. Immediately following the exercise, his directly held share count stood at 147,685 shares, according to the filing. He then disposed of 1,907 shares (transaction code S) at a weighted-average price of $60.779, with actual sale prices ranging from $60.385 to $61.24, and subsequently sold an additional 343 shares at a weighted-average price of $61.57, with prices ranging from $61.40 to $61.88. After these transactions, his direct beneficial ownership totaled 145,435 shares.
The filing states that both sales "were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025." The Form 4 was signed by Peter N. Efremenko as Attorney-in-Fact for Jim Wassil on November 4, 2026. The filing also notes that full information regarding the number of shares sold at each separate price within the weighted-average ranges will be provided upon request to the SEC, the issuer, or a security holder of the issuer.
What Was Disclosed
Vaxcyte EVP Jim Wassil filed a Form 4 reporting a stock option exercise of 2,250 shares at $5.35 and two subsequent sales totaling 2,250 shares on November 2, 2026, all under a pre-established 10b5-1 plan, leaving him with 145,435 directly held shares.





Please wait processing your request...